#ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide...

CHICAGO, IL USA (UroToday.com) - Full Title: #ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer who have bone metastases

Presented by Daniel Petrylak, MD,1 Julie A. Rosenberg, MD,2 Vittorio Luigi Garosi, MD, PhD,3 Jonathan Siegel,2 and Jonathan Goldin, MD4 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 petrylak poster thumb

Click HERE to listen to an exclusive interview with Daniel Petrylak, MD, one of the authors of the study

1Yale Cancer Center, New Haven, CT USA
2Bayer HealthCare Pharmaceuticals, Inc., Whippany NJ, USA
3Bayer S.p.A., Milan, Italy
4UCLA Radiology Science, Los Angeles, CA USA

 

email news signup